About S-adenosylmethionine synthase isoform type-2
S-adenosylmethionine synthase isoform type-2 (MAT2A) is a protein
from Homo sapiens identified by UniProt accession
P31153, 395 residues long.
MolForge cross-references it against 0 known binders and
158 disease associations.
Target properties
| Protein name | S-adenosylmethionine synthase isoform type-2 |
| UniProt accession | P31153 |
| Gene | MAT2A |
| Organism | Homo sapiens |
| Length | 395 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (158)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.54
- platelet count · score 0.35
- neuroinflammatory disorder · score 0.34
- prostate carcinoma · score 0.28
- coronary artery disease · score 0.28
- platelet crit · score 0.26
- angina pectoris · score 0.26
- Myocardial Ischemia · score 0.23
- sitting height measurement · score 0.22
- myocardial infarction · score 0.22
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P31153-F1 | alphafold | PREDICTED | 96.06 | — |
Amino-acid sequence (395 residues)
MNGQLNGFHE AFIEEGTFLF TSESVGEGHP DKICDQISDA VLDAHLQQDP DAKVACETVA KTGMILLAGE ITSRAAVDYQ KVVREAVKHI GYDDSSKGFD YKTCNVLVAL EQQSPDIAQG VHLDRNEEDI GAGDQGLMFG YATDETEECM PLTIVLAHKL NAKLAELRRN GTLPWLRPDS KTQVTVQYMQ DRGAVLPIRV HTIVISVQHD EEVCLDEMRD ALKEKVIKAV VPAKYLDEDT IYHLQPSGRF VIGGPQGDAG LTGRKIIVDT YGGWGAHGGG AFSGKDYTKV DRSAAYAARW VAKSLVKGGL CRRVLVQVSY AIGVSHPLSI SIFHYGTSQK SERELLEIVK KNFDLRPGVI VRDLDLKKPI YQRTAAYGHF GRDSFPWEVP KKLKY
Explore S-adenosylmethionine synthase isoform type-2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets